EZH2 and diffuse large B-cell lymphoma: On the other hand, CPI-1205 is an orally bioavailable EZH2 inhibitor with a unique indole-based structure different from pyridine-based compounds such as GSK126 and tazemetostat.1347 Preclinical studies have demonstrated that CPI-1205 significantly inhibits tumor growth in DLBCL xenograft models, with good oral bioavailability and an acceptable safety profile in rats and dogs.